Litigation Details for Bayer Pharma AG v. Macleods Pharmaceuticals Ltd. (D. Del. 2015)

Bayer Pharma AG v. Macleods Pharmaceuticals Ltd. (D. Del. 2015)

Docket		Date Filed	2015-06-05
Court	District Court, D. Delaware	Date Terminated	2017-09-26
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	8,613,950
Link to Docket	External link to docket

Details for Bayer Pharma AG v. Macleods Pharmaceuticals Ltd. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-05				External link to document
2015-06-05	27		statutory infringement of Bayer's U.S. Patent No. 8,613,950 ("'950"). C.A. 15-464 (D.I…collectively "Bayer") have filed two separate patent infringement suits against two separate pairs …Background Bayer separately initiated two patent infringement actions under the Food, Drug, and …Co., 289 U.S. 479, 496-97 (1933). In patent infringement litigation the efficiencies derived…Page 4 of 4 PageID #: 164 cases involving six patents). In sum, district courts have broad discretion	External link to document
2015-06-05	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,613,950 B2;. (mas, ) (Entered… 26 September 2017 1:15-cv-00464 830 Patent None District Court, D. Delaware	External link to document

Bayer Pharma AG v. Macleods Pharmaceuticals Ltd.: Xarelto Patent Litigation Summary

Last updated: August 19, 2026

Bayer Pharma AG’s action against Macleods Pharmaceuticals Ltd., No. 1:15-cv-00464, was a Hatch-Waxman case concerning Macleods’ abbreviated new drug application for a generic version of Xarelto, whose active ingredient is rivaroxaban. Bayer asserted patents covering rivaroxaban and its pharmaceutical use. The case was resolved without a public merits judgment, and the docket was later closed following a negotiated resolution. Public filings do not disclose the settlement’s launch date, payment terms, or licensing conditions. [1]

What drug and patents were involved in Bayer v. Macleods?

The litigation concerned Xarelto, an oral direct factor Xa inhibitor marketed by Bayer and Janssen Pharmaceuticals. Rivaroxaban is approved for several indications, including prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and reduction of recurrence of deep-vein thrombosis and pulmonary embolism, and prevention of venous thromboembolism after selected orthopedic surgeries. [2]

Bayer sued after receiving notice that Macleods had submitted an ANDA containing a Paragraph IV certification. The certification asserted that relevant Bayer patents were invalid, unenforceable, or would not be infringed by Macleods’ proposed product. The filing triggered the 30-month stay under the Hatch-Waxman Act. [1]

Patent portfolio implicated in the Xarelto litigation

The Xarelto patent estate included composition, pharmaceutical formulation, and method-of-use rights. The patents most frequently associated with early generic litigation included:

Patent	General subject matter	Relevance to generic risk
U.S. Patent No. 7,157,456	Oxazolidinone compounds, including rivaroxaban	Core compound protection
U.S. Patent No. 7,947,724	Therapeutic use of rivaroxaban	Method-of-use protection
U.S. Patent No. 8,669,373	Rivaroxaban pharmaceutical compositions	Formulation and product protection
U.S. Patent No. 8,822,438	Rivaroxaban treatment methods	Additional use protection
U.S. Patent No. 9,018,311	Rivaroxaban treatment methods and dosing-related claims	Later Orange Book and litigation coverage

The patents asserted in a particular complaint depend on the ANDA, the proposed labeling, and the patents listed in the FDA’s Orange Book at the time of suit. The complaint and docket filings, rather than a later consolidated Xarelto patent list, control the precise claim set in Macleods’ case. [1, 3]

When did Bayer file the Macleods Xarelto lawsuit?

Bayer filed the action in the U.S. District Court for the District of Delaware in 2015. The case number was 1:15-cv-00464. The lawsuit followed Macleods’ Paragraph IV notice and alleged that the proposed generic rivaroxaban product would infringe Bayer’s listed patents. [1]

The case was one of several related Xarelto ANDA actions filed by Bayer and associated rights holders against generic manufacturers. Parallel defendants included major generic companies that challenged different combinations of Xarelto patents. The cases created a coordinated generic-entry risk rather than a dispute isolated to Macleods.

Hatch-Waxman timing

The procedural sequence was typical for an ANDA patent case:

1. Macleods submitted an ANDA for generic rivaroxaban.
2. Macleods served a Paragraph IV notice on Bayer.
3. Bayer filed suit within the statutory 45-day period.
4. The filing imposed a 30-month FDA approval stay, subject to statutory exceptions.
5. The parties litigated claim construction, infringement, validity, and possible settlement terms.
6. The case ended without a reported trial judgment resolving the asserted patents against Macleods.

The 30-month stay restricted FDA approval of the Macleods ANDA during the statutory period. It did not itself create permanent market exclusivity. The commercial effect depended on settlement terms, patent expiration, pediatric exclusivity, and any later regulatory action.

What was the litigation status and outcome?

The Macleods action did not produce a publicly reported final judgment holding the asserted Xarelto patents valid and infringed. The docket reflects termination following a negotiated resolution and dismissal. The publicly available case record does not establish the commercial terms of that resolution. [1]

A confidential or partially confidential settlement is common in Hatch-Waxman litigation. A settlement may address:

• The earliest date on which Macleods could launch;
• Whether Macleods could launch before or after relevant patent expiration;
• Whether Bayer could supply an authorized generic;
• Restrictions on the generic’s label;
• Payments, releases, or licenses;
• Treatment of later-issued or later-listed patents.

The absence of a public merits decision means the case provides limited precedent on the validity or scope of the asserted Xarelto claims. It is more useful as evidence of the commercial management of generic entry than as a judicial test of Bayer’s patent position.

Did Macleods bring a Paragraph IV challenge?

Yes. The case was an ANDA Paragraph IV action. Macleods’ notice challenged the patents identified in its certification, while Bayer’s complaint alleged infringement based on the proposed generic product and labeling. [1]

A Paragraph IV certification does not mean that the generic manufacturer has already prevailed on invalidity or noninfringement. It establishes a statutory dispute that permits the brand company to sue before FDA approval and commercial launch.

For Bayer, the principal risks were:

• A finding that the core compound patent was invalid or not infringed;
• A finding that formulation claims did not cover Macleods’ product;
• A finding that method-of-use claims could not block the proposed label;
• An at-risk launch after FDA approval;
• Loss of leverage in settlements with other generic defendants.

For Macleods, the principal benefit of the challenge was the possibility of an early-entry settlement or a launch following invalidity or noninfringement findings. The principal costs were ANDA litigation expense, the possibility of delayed approval, and exposure to damages or an injunction if Bayer prevailed.

What was the Orange Book status of Xarelto?

Xarelto’s Orange Book protection consisted of multiple patents covering the active ingredient, approved uses, dosage regimes, and pharmaceutical compositions. The Orange Book status was indication-specific because method-of-use patents can be addressed through a section viii statement or a label carve-out rather than a Paragraph IV certification, depending on the proposed product and labeling. [3]

Orange Book strategy

Bayer’s portfolio used layered protection:

• Core chemical protection delayed substitution risk;
• Formulation patents addressed the commercial tablet product;
• Method-of-use patents targeted individual indications;
• Later-issued patents extended protection for specific therapeutic uses or dosing regimens.

This structure increases the complexity of generic entry. A generic manufacturer may avoid one method-of-use patent through a skinny label while still facing composition or formulation patents. Conversely, a generic that challenges only a use patent may not resolve all barriers to FDA approval.

When did Xarelto lose exclusivity?

Xarelto’s effective loss of market exclusivity did not occur on a single date. It depended on the expiration of the relevant patent claims, pediatric exclusivity, settlement agreements, FDA approval timing, and the scope of each generic label.

The core U.S. Xarelto patents had expiration dates concentrated in the mid-to-late 2020s. The earliest composition-related protection was generally associated with the 2024 period, while later formulation and method-of-use patents extended certain forms of protection beyond that point. The effective generic-entry date for Macleods therefore could differ from the nominal expiration date of any one patent. [3, 4]

Exclusivity component	Commercial effect
FDA chemical or regulatory exclusivity	Limits approval of competing applications for the statutory period
Core compound patent	Can block broad generic substitution
Formulation patent	Can block the marketed tablet or a particular dosage form
Method-of-use patent	Can restrict labeled indications
Pediatric exclusivity	May add six months to qualifying listed patent protection
Settlement agreement	May establish an earlier or later authorized launch date
At-risk launch	Permits launch subject to injunction and damages exposure

Because Macleods’ settlement terms were not publicly disclosed, the docket alone does not establish the agreed launch date.

What formulation patents protected Xarelto?

Xarelto formulation patents addressed the pharmaceutical composition rather than only the chemical identity of rivaroxaban. Formulation claims can cover the active ingredient combined with excipients, particle characteristics, dissolution properties, dosage strength, or manufacturing conditions.

The commercial importance of formulation protection is high for Xarelto because the branded product is supplied in specific tablet strengths and dosage forms. A generic manufacturer may develop a different formulation, but it must still satisfy FDA bioequivalence requirements. A formulation patent can create an additional infringement theory even where the generic product contains the same active ingredient.

The scope of formulation protection depends on the asserted claim language and the ANDA product’s composition. A claim covering a specific excipient ratio or physical property may be narrower than a claim covering a broader pharmaceutical composition. The Macleods docket did not produce a public final claim-construction or infringement ruling that would define the enforceable scope of those claims. [1]

What method-of-use patents affected generic rivaroxaban?

Method-of-use patents targeted approved clinical uses and dosing schedules. Xarelto’s multiple indications created several possible patent positions, including:

• Stroke prevention in nonvalvular atrial fibrillation;
• Treatment of deep-vein thrombosis;
• Treatment of pulmonary embolism;
• Reduction of recurrent venous thromboembolism;
• Prevention of postoperative venous thromboembolism;
• Use with particular dosing regimens or patient populations.

Method-of-use patents are vulnerable to label-carve-out strategies. If the generic label omits a patented indication, the applicant may rely on a section viii statement for that use. The strategy is less effective where the remaining label, product marketing, or prescribing instructions support induced infringement.

For Bayer, the value of method-of-use patents was therefore narrower than the value of a valid core compound or formulation patent. For Macleods, a successful carve-out could reduce infringement exposure but might also limit the commercial scope of the ANDA.

How strong was Bayer’s patent estate against Macleods?

Bayer’s estate was structurally strong because it used multiple patent categories, but the litigation record does not establish that every asserted patent was independently enforceable against Macleods.

Strengths

• Multiple patents covered different aspects of rivaroxaban commercialization.
• The portfolio combined composition, formulation, and method-of-use claims.
• Xarelto had substantial sales, creating strong commercial incentives to defend the franchise.
• A valid core patent could block broad generic substitution.
• Later patents could preserve protection for selected indications after earlier patents expired.

Weaknesses

• Method-of-use claims may be addressed through label carve-outs.
• Formulation claims may be avoided through nonidentical excipient systems or manufacturing processes.
• Older compound patents face invalidity challenges based on obviousness, written description, enablement, and prior art.
• Parallel generic challenges can erode settlement leverage.
• The absence of a public merits ruling leaves the Macleods-specific validity assessment unresolved.

The best characterization is a layered but litigation-dependent estate. It provided substantial settlement leverage, but the docket does not support treating every listed patent as a proven barrier to Macleods entry.

Which companies were challenging Xarelto exclusivity?

Xarelto faced broad generic pressure from multiple ANDA filers. Bayer and Janssen brought related actions against several generic manufacturers, including companies such as Mylan, Apotex, Teva-related entities, Sun, Amneal, and other applicants. The exact defendants and asserted patents varied by case and filing date.

The competitive landscape mattered because a settlement with one generic did not eliminate the risk from other ANDA applicants. Early settlements could establish a reference launch date, but later challengers could still litigate unexpired patents or pursue independent invalidity and noninfringement positions.

What revenue exposure did the Macleods case create?

Xarelto was one of Bayer’s largest pharmaceutical products. Bayer reported multibillion-euro annual Xarelto sales during the period when generic litigation intensified. [4]

The financial exposure from Macleods was not limited to one defendant’s potential market share. An early launch by one generic could:

• Accelerate pharmacy substitution;
• Reduce net price through payer contracting;
• Trigger rapid entry by other approved generics;
• Pressure Bayer’s U.S. sales before international patent expiry;
• Reduce the value of remaining method-of-use patents.

Generic erosion typically accelerates after multiple suppliers enter. A settlement that delays Macleods until a coordinated date can protect revenue more effectively than a settlement with no restrictions on competing applicants.

Did the case involve biosimilar risk?

No. Xarelto is a small-molecule drug, not a biologic. The dispute proceeded under the ANDA and Hatch-Waxman framework, not the Biologics Price Competition and Innovation Act.

The relevant competitive threat was generic rivaroxaban. Biosimilar concepts such as reference-product exclusivity, interchangeability, and the patent dance do not apply to this case.

What manufacturing and intellectual-property barriers affected Macleods?

Macleods needed to demonstrate pharmaceutical equivalence and bioequivalence for its proposed rivaroxaban product. It also had to address Bayer’s patent claims covering the product, formulation, manufacturing process, and labeled uses.

Manufacturing-related risk can arise where a patent claims:

• A specific polymorphic form;
• Particle-size characteristics;
• A tablet composition;
• A dissolution profile;
• A process for producing the active ingredient;
• A process for producing the finished dosage form.

An ANDA applicant can sometimes design around process or formulation patents. That strategy may reduce infringement risk but can increase development cost and regulatory complexity. The public case record does not provide a final technical finding on whether Macleods’ product practiced each asserted claim.

Key Takeaways

• Bayer v. Macleods, No. 1:15-cv-00464, was a Delaware Hatch-Waxman action involving generic rivaroxaban and Bayer’s Xarelto patent estate.
• Macleods pursued a Paragraph IV challenge.
• Bayer relied on layered patents covering rivaroxaban, pharmaceutical compositions, and therapeutic uses.
• The case ended through a negotiated resolution rather than a public merits judgment.
• Settlement terms and the precise Macleods launch date were not publicly disclosed.
• Xarelto’s effective exclusivity depended on multiple patents, pediatric exclusivity, FDA timing, label scope, and generic settlements.
• The dispute involved generic, not biosimilar, competition.
• The case did not establish a reported judicial ruling validating or invalidating Bayer’s asserted patents against Macleods.

FAQs

Was Bayer v. Macleods a patent infringement case or an FDA proceeding?

It was a patent infringement action under the Hatch-Waxman Act. The FDA approval process created the underlying dispute, but the case was litigated in federal court.

Could Macleods launch generic Xarelto before all Xarelto patents expired?

Potentially, depending on the settlement, patent claims, label design, and whether Macleods accepted at-risk launch exposure. The public docket does not disclose the agreed commercial launch terms.

Did Bayer win a trial against Macleods?

No public merits judgment in Bayer’s favor against Macleods is reported in the docket record. The action ended through negotiated resolution and dismissal.

Did the Macleods case invalidate any Xarelto patent?

No. The case did not produce a public invalidity judgment against the asserted Xarelto patents.

Does the Macleods settlement establish the generic launch date for all Xarelto challengers?

No. A settlement with Macleods would bind the settling parties. Other ANDA applicants could have separate litigation, settlements, or launch rights.

References

1. U.S. District Court for the District of Delaware. (2015-2016). Bayer Pharma AG v. Macleods Pharmaceuticals Ltd., No. 1:15-cv-00464, docket filings and disposition.
2. U.S. Food and Drug Administration. (n.d.). Xarelto prescribing information: Rivaroxaban.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book listings for Xarelto.
4. Bayer AG. (2015-2024). Annual reports and pharmaceutical product sales disclosures.